Akero Therapeutics Inc (NQ: AKRO )
27.01
+0.40
(+1.50%)
Streaming Delayed Price
Updated: 11:09 AM EDT, Jul 31, 2024
Add to My Watchlist
Press Releases about Akero Therapeutics Inc
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
From Akero Therapeutics
Via GlobeNewswire
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
From Akero Therapeutics
Via GlobeNewswire
![](https://www.marketbeat.com/logos/articles/med_20230608115114_3-mid-caps-you-havent-heard-of-but-need-to-know-ab.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
December 08, 2022
From Akero Therapeutics
Via GlobeNewswire
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
From Akero Therapeutics
Via GlobeNewswire
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
![](https://ml.globenewswire.com/media/cb85fa28-c91f-4e69-9ab0-37bd11d39425/small/akero-logo-with-white-space-1-jpg.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.